Paliperidone

BreastfeedingGeriatricPediatric
  • TRADE NAME: Invega (Janssen)
  • INDICATIONS: Schizophrenia
  • CLASS: Antipsychotic
  • HALF-LIFE: ~23 hours
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

ACE inhibitors, Alcohol, Alpha blockers, Amphetamines, Angiotensin II receptor antagonists, Carbamazepine, CNS depressants, Dopamine agonists, Droperidol, General anesthetics, Itraconazole, Levodopa, Levomepromazine, Lithium, Methylphenidate, Metoclopramide, Myleosuppressives, P-glycoprotein inhibitors or inducers, Quinagolide, Risperidone, Tetrabenazine, Valproic Acid

PREGNANCY CATEGORY: C

NOTE

Invega is not recommended for patients with creatinine clearance below 10 mL/min.

Paliperidone is the active metabolite of risperidone (see separate entry).

BLACK BOX WARNING
INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSIS

See full prescribing information for complete boxed warning.

Our database has 116 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
GENITOURINARY.
HEMATOLOGIC.
LOCAL.
NEUROMUSCULAR/SKELETAL.
OCULAR.
RENAL.
RESPIRATORY.
OTHER.


Visit Informa

Click on the DRUG REVIEW ARTICLE tab (above) to see a review of paliperidone in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)

Page last updated 08/01/2023

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top